This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chambers, S A Articles by Isenberg, D Search for Related Content PubMed PubMed Citation Articles by Chambers, S A Articles by Isenberg, D Social Bookmarking                   What's this?

Anti-B cell therapy (Rituximab) in the treatment of autoimmune diseases

Centre for Rheumatology, The Middlesex Hospital, University College, London, UK

D Isenberg

Centre for Rheumatology, The Middlesex Hospital, University College, London, UK, D.Isenberg{at}ucl.ac.uk

The use of B cell depletion as a mode of treatment for non-Hodgkin’s lymphoma was first utilized in 1997 when Rituximab, a chimeric human-mouse monoclonal antibody which has a high affinity to the CD20 antigen expressed on B cells, became available. Over 500 000 lymphoma patients have been treated worldwide with this drug and it has a good safety record. The notion that B cells might be critical to the development of rheumatoid arthritis led to the extension of the use of B cell depletion to this condition and a recent double blind controlled trial has shown very encouraging results. In addition, B cell depletion either using Rituximab alone, or in combination with cyclophosphamide and corticosteroids has also been reported to have been of great benefit in some patients with severe systemic lupus erythematosus albeit in open label studies. This review considers the mechanism of action of the drug, the clinical trials that have been reported, and tries to place its current use in patients with autoimmune rheumatic disease in context.

Key Words: B cell depletion • CD20 • rheumatoid arthritis • Rituximab • systemic lupus erythematosus

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				C B Driver, M Ishimori, and M H Weisman The B cell in systemic lupus erythaematosus: a rational target for more effective therapy Ann Rheum Dis, October 1, 2008; 67(10): 1374 - 1381. [Abstract] [Full Text] [PDF]

				A. Rahman and D. A. Isenberg Systemic Lupus Erythematosus N. Engl. J. Med., February 28, 2008; 358(9): 929 - 939. [Full Text] [PDF]

				G. Cianchini, R. Corona, A. Frezzolini, M. Ruffelli, B. Didona, and P. Puddu Treatment of Severe Pemphigus With Rituximab: Report of 12 Cases and a Review of the Literature Arch Dermatol, August 1, 2007; 143(8): 1033 - 1038. [Abstract] [Full Text] [PDF]

				R. M. Sharkey and D. M. Goldenberg Targeted Therapy of Cancer: New Prospects for Antibodies and Immunoconjugates CA Cancer J Clin, July 1, 2006; 56(4): 226 - 243. [Abstract] [Full Text] [PDF]

				P. Ruggenenti, C. Chiurchiu, M. Abbate, A. Perna, P. Cravedi, M. Bontempelli, and G. Remuzzi Rituximab for Idiopathic Membranous Nephropathy: Who Can Benefit? Clin. J. Am. Soc. Nephrol., July 1, 2006; 1(4): 738 - 748. [Abstract] [Full Text] [PDF]

				J. M Stachnik Rituximab in the Treatment of Acquired Hemophilia Ann. Pharmacother., June 1, 2006; 40(6): 1151 - 1157. [Abstract] [Full Text] [PDF]